$LEXX
Lexaria Bioscience Corp. Stock $lexx

$lexx Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000164033421002981 Filed on November 29, 2021

Income Statement

Concept	2021	2020 Q3	2020
Revenue	$722.7K	$130.0K	$314.8K
YoY Change	129.59%	0.0%	41.41%
Cost Of Revenue	$175.3K	$10.00K	$99.38K
YoY Change	76.44%	0.0%	396.89%
Gross Profit	$547.4K	$120.0K	$215.4K
YoY Change	154.11%	9.09%	7.71%
Gross Profit Margin	75.74%	92.31%	68.43%
Selling, General & Admin	$4.805M	$800.0K	$3.820M
YoY Change	25.79%	-21.57%	2.69%
% of Gross Profit	877.82%	666.67%	1773.32%
Research & Development	$1.263M	$70.00K	$387.1K
YoY Change	226.27%	-56.25%	-30.88%
% of Gross Profit	230.71%	58.33%	179.69%
Depreciation & Amortization	$111.7K	$30.00K	$112.8K
YoY Change	-0.92%	0.0%	86.21%
% of Gross Profit	20.41%	25.0%	52.34%
Operating Expenses	$6.234M	$900.0K	$4.364M
YoY Change	42.85%	-25.62%	0.14%
Operating Profit	-$5.687M	-$780.0K	-$4.149M
YoY Change	37.07%	-29.09%	-0.22%
Interest Expense	-$166.3K	$0.00	-$40.00K
YoY Change	315.65%	-100.0%	100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$4.170M	-$770.0K	-$3.987M
YoY Change	4.59%	-31.25%	-4.12%
Income Tax	$6.093K		$2.319K
% Of Pretax Income
Net Earnings	-$4.186M	-$715.0K	-$4.085M
YoY Change	2.49%	-33.8%	-199.62%
Net Earnings / Revenue	-579.21%	-549.97%	-1297.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$917.0K	-$7.896K	-$1.419M
COMMON SHARES
Basic Shares Outstanding		89.59M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021	2020 Q3	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.75M	$1.310M	$1.310M
YoY Change	797.07%	-2.96%	-2.96%
Cash & Equivalents		$1.294M	$1.290M
Short-Term Investments	$833.8K	$20.00K	$20.00K
Other Short-Term Assets	$319.3K	$290.0K	$290.0K
YoY Change	10.09%	314.29%	314.29%
Inventory	$29.65K	$116.9K	$120.0K
Prepaid Expenses		$182.1K
Receivables	$16.55K	$313.9K	$80.00K
Other Receivables	$325.9K	$130.0K	$130.0K
Total Short-Term Assets	$12.44M	$1.926M	$1.930M
YoY Change	544.71%	5.89%	6.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$459.3K	$483.4K	$610.0K
YoY Change	-24.71%	-18.25%	3.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$823.9K	$902.3K	$900.0K
YoY Change	-8.46%	5.36%	4.65%
TOTAL ASSETS
Total Short-Term Assets	$12.44M	$1.926M	$1.930M
Total Long-Term Assets	$823.9K	$902.3K	$900.0K
Total Assets	$13.27M	$2.828M	$2.830M
YoY Change	368.79%	5.72%	5.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$54.67K	$50.00K	$50.00K
YoY Change	9.34%	66.67%	66.67%
Accrued Expenses	$85.46K	$70.00K	$70.00K
YoY Change	22.09%	-30.0%	-30.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.930K
YoY Change
Total Short-Term Liabilities	$153.3K	$225.9K	$230.0K
YoY Change	-33.36%	22.44%	27.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$30.00K	$30.00K
YoY Change	-100.0%
Other Long-Term Liabilities	$49.99K	$90.00K	$90.00K
YoY Change	-44.46%
Total Long-Term Liabilities	$49.99K	$120.1K	$120.0K
YoY Change	-58.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$153.3K	$225.9K	$230.0K
Total Long-Term Liabilities	$49.99K	$120.1K	$120.0K
Total Liabilities	$1.180K	$346.0K	$300.0K
YoY Change	-99.61%	87.52%	3.45%
SHAREHOLDERS EQUITY
Retained Earnings		-$27.80M
YoY Change		16.48%
Common Stock		$3.001K
YoY Change		-96.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.27M	$2.482M	$2.530M
YoY Change
Total Liabilities & Shareholders Equity	$13.27M	$2.828M	$2.830M
YoY Change	368.79%	5.72%	5.6%

Cashflow Statement

Concept	2021	2020 Q3	2020
OPERATING ACTIVITIES
Net Income	-$4.186M	-$715.0K	-$4.085M
YoY Change	2.49%	-33.8%	-199.62%
Depreciation, Depletion And Amortization	$111.7K	$30.00K	$112.8K
YoY Change	-0.92%	0.0%	86.21%
Cash From Operating Activities	-$3.990M	-$680.0K	-$2.619M
YoY Change	52.35%	-8.11%	-12.87%
INVESTING ACTIVITIES
Capital Expenditures	-$79.49K	-$10.00K	-$30.00K
YoY Change	164.97%	0.0%	-104.64%
Acquisitions
YoY Change
Other Investing Activities	$273.4K	$0.00	$10.00K
YoY Change	2633.7%	-100.0%	-108.33%
Cash From Investing Activities	$193.9K	-$20.00K	-$26.84K
YoY Change	-822.27%	-33.33%	-96.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$22.74K
YoY Change
Cash From Financing Activities	$13.42M	-40.00K	$2.654M
YoY Change	405.6%	-166.67%	-20.29%
NET CHANGE
Cash From Operating Activities	-$3.990M	-680.0K	-$2.619M
Cash From Investing Activities	$193.9K	-20.00K	-$26.84K
Cash From Financing Activities	$13.42M	-40.00K	$2.654M
Net Change In Cash	$9.624M	-740.0K	$8.602K
YoY Change	111781.52%	4.23%	-100.23%
FREE CASH FLOW
Cash From Operating Activities	-$3.990M	-$680.0K	-$2.619M
Capital Expenditures	-$79.49K	-$10.00K	-$30.00K
Free Cash Flow	-$3.910M	-$670.0K	-$2.589M
YoY Change	51.04%	-8.22%	-29.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	50344	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.76
CY2020Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	483357	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	84900	shares
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	823877	USD
CY2020Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	902277	USD
CY2021Q3	us-gaap	Assets Assets	13266817	USD
CY2020Q3	us-gaap	Assets Assets	2828238	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	100723	USD
CY2020Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	86920	USD
CY2021Q3	us-gaap	Deferred Revenue DeferredRevenue	0	USD
CY2020Q3	us-gaap	Deferred Revenue DeferredRevenue	44255	USD
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	5223	USD
CY2020Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	58704	USD
CY2021Q3	us-gaap	Loans Payable Current LoansPayableCurrent	7926	USD
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.41
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	206170	shares
CY2020Q3	us-gaap	Loans Payable Current LoansPayableCurrent	0	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	39404	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	36038	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	153276	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	225917	USD
CY2021Q3	us-gaap	Other Liabilities OtherLiabilities	49989	USD
CY2020Q3	us-gaap	Other Liabilities OtherLiabilities	89393	USD
CY2021Q3	us-gaap	Loans Payable LoansPayable	0	USD
CY2020Q3	us-gaap	Loans Payable LoansPayable	30670	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	49989	USD
CY2020Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	120063	USD
CY2021Q3	us-gaap	Liabilities Liabilities	203265	USD
CY2020Q3	us-gaap	Liabilities Liabilities	345980	USD
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	220000000	shares
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5726699	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10917797	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1293749	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	833841	USD
CY2020Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	19321	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	342401	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	313925	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	29648	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	116871	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	319253	USD
CY2020Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	182095	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	12442940	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	1925961	USD
CY2021Q3	lexx	Right Of Use Assets RightOfUseAssets	91041	USD
CY2020Q3	lexx	Right Of Use Assets RightOfUseAssets	126920	USD
CY2021Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	364623	USD
CY2020Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	292000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	368213	USD
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5726699	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3001476	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	5727	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	3001	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45089114	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30324398	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31829204	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27802198	USD
CY2021Q3	lexx	Equity Attributable To Shareholders Of The Company EquityAttributableToShareholdersOfTheCompany	13265637	USD
CY2020Q3	lexx	Equity Attributable To Shareholders Of The Company EquityAttributableToShareholdersOfTheCompany	2525201	USD
CY2021Q3	us-gaap	Minority Interest MinorityInterest	-202085	USD
CY2020Q3	us-gaap	Minority Interest MinorityInterest	-42943	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	13063552	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	2482258	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13266817	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2828238	USD
CY2021	us-gaap	Revenues Revenues	722738	USD
CY2020	us-gaap	Revenues Revenues	314793	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	175346	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	99378	USD
CY2021	us-gaap	Gross Profit GrossProfit	547392	USD
CY2020	us-gaap	Gross Profit GrossProfit	215415	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1262895	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	387074	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4971349	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3977138	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	6234244	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	4364212	USD
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5686852	USD
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4148797	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1522704	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-22000	USD
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	64184	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4186148	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-4084613	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4027006	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3933996	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-159142	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-150617	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.95
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.01
CY2020	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	0.02
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4391446	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2773376	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4186148	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	410007	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1139270	USD
CY2021	us-gaap	Depreciation Depreciation	111718	USD
CY2020	us-gaap	Depreciation Depreciation	112750	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2482	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	8240	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50500	USD
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.41
CY2020	lexx	Income From Ongoing Operations IncomeFromOngoingOperations	384543	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.30
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	29.51
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	161600	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.66
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	lexx	Income From Ongoing Operations IncomeFromOngoingOperations	722738	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	44816	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7469	USD
CY2021Q3	lexx	Lessee Operating Lease Liability Payments Due Thereafter LesseeOperatingLeaseLiabilityPaymentsDueThereafter	0	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	96884	USD
CY2021Q3	lexx	Operating Imputed Interest OperatingImputedInterest	-7491	USD
CY2021Q3	lexx	Present Value Of Operating Lease Liabilities PresentValueOfOperatingLeaseLiabilities	89393	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39404	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	49989	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35879	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	33342	USD
CY2021	lexx	Realized Loss On Disposal Of Marketable Securities RealizedLossOnDisposalOfMarketableSecurities	0	USD
CY2020	lexx	Realized Loss On Disposal Of Marketable Securities RealizedLossOnDisposalOfMarketableSecurities	18198	USD
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	166255	USD
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	19893	USD
CY2021	lexx	Gain On Asset Disposal GainOnAssetDisposal	-1522704	USD
CY2020	lexx	Gain On Asset Disposal GainOnAssetDisposal	0	USD
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	85000	USD
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	100000	USD
CY2021	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	785895	USD
CY2020	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	168833	USD
CY2021	lexx	Lease Accretion LeaseAccretion	7912	USD
CY2020	lexx	Lease Accretion LeaseAccretion	9665	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	189580	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-90780	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	95037	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4213	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-137158	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-113168	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13803	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-49491	USD
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-53481	USD
CY2020	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	10608	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-44255	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	44255	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3989678	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2618785	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6802	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	79493	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	33645	USD
CY2021	lexx	Asset Disposition AssetDisposition	273373	USD
CY2020	lexx	Asset Disposition AssetDisposition	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	193880	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26843	USD
CY2021	lexx	Long Term Loan LongTermLoan	-22744	USD
CY2020	lexx	Long Term Loan LongTermLoan	30670	USD
CY2021	lexx	Lease Payments LeasePayments	43950	USD
CY2020	lexx	Lease Payments LeasePayments	44496	USD
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9471497	USD
CY2020	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2668056	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4015043	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13419846	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2654230	USD
CY2021	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9624048	USD
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8602	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1293749	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1285147	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10917797	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1293749	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	16297	USD
CY2021Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	168760	USD
CY2020Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	21878	USD
CY2021Q3	lexx	Prepaid Legal Fees PrepaidLegalFees	31380	USD
CY2020Q3	lexx	Prepaid Legal Fees PrepaidLegalFees	47498	USD
CY2021Q3	lexx	Prepaid Licence And Filing Fees Due PrepaidLicenceAndFilingFeesDue	19500	USD
CY2020Q3	lexx	Prepaid Licence And Filing Fees Due PrepaidLicenceAndFilingFeesDue	8541	USD
CY2021Q3	us-gaap	Prepaid Insurance PrepaidInsurance	80863	USD
CY2020Q3	us-gaap	Prepaid Insurance PrepaidInsurance	78792	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	319253	USD
CY2020Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	182095	USD
CY2021Q3	us-gaap	Trading Securities Cost TradingSecuritiesCost	1037025	USD
CY2021	lexx	Unrealized Gains UnrealizedGains	16243	USD
CY2021	lexx	Unrealized Losses UnrealizedLosses	-219427	USD
CY2021Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	273373	USD
CY2021	lexx	Shares Received On Disposal Of Asset SharesReceivedOnDisposalOfAsset	468264	USD
CY2021Q3	lexx	Shares Receivable On Disposal Of Asset SharesReceivableOnDisposalOfAsset	781067	USD
CY2021	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	3000	USD
CY2020	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	69750	USD
CY2021	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	25000	USD
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-22000	USD
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	64184	USD
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	-22000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	64184	USD
CY2021	lexx	Discontinued Operations Change In Working Capital DiscontinuedOperationsChangeInWorkingCapital	25000	USD
CY2020	lexx	Discontinued Operations Change In Working Capital DiscontinuedOperationsChangeInWorkingCapital	-99000	USD
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	3000	USD
CY2020	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-34816	USD
CY2021	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	3000	USD
CY2021Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	0	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30030	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	12978	USD
CY2021	lexx	Marketable Securities Received On Amounts Receivable MarketableSecuritiesReceivedOnAmountsReceivable	893493	USD
CY2020	lexx	Marketable Securities Received On Amounts Receivable MarketableSecuritiesReceivedOnAmountsReceivable	0	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	2490712	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	100000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1139270	USD
CY2020	lexx	Warrants Issued For Service WarrantsIssuedForService	168833	USD
CY2020	lexx	Private Placements Amount PrivatePlacementsAmount	2638026	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-150617	USD
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	85000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	410007	USD
CY2021	lexx	Warrants Issued For Service WarrantsIssuedForService	785895	USD
CY2021	lexx	Exercise Of Warrants Amount ExerciseOfWarrantsAmount	4015043	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9471497	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-159142	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. Nature of Business</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria Bioscience Corp. (“Lexaria”, “we”, “our” or the “Company”) is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“API”) using our proprietary DehydraTECH drug delivery technology. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenues are received from licensing the Company’s patented technology to partners who pay either a license fee to use DehydraTECH in the manufacturing of their own products or purchase DehydraTECH manufactured products made to their specifications by Lexaria. The Company has relationships with several consumer products companies in the CBD and nutraceuticals spaces that use Lexaria’s technology in consumer goods being sold online and at retailers in the US and Canada. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Going Concern Consideration</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”) applicable to a going concern which assumes the Company will have sufficient funds to pay it operational, research and development and capital expenditures for a period of at least 12 months from the date this financial report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, the Company has incurred significant operating and net losses. The losses attributable to common shareholders were $4.2m, $4.1m and $4.2m for the years ended August 31, 2021, 2020 and 2019, respectively. As of August 31, 2021, we had an accumulated deficit of $31.8m. We expect to continue to incur significant operational expenses and net losses in the upcoming 12 months. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the stage and complexity of our R&D studies and related expenditures, the receipt of additional payments on the licencing of our technology, if any, and the receipt of payments under any current or future collaborations we may enter into. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 12, 2021, the Company closed an underwritten public offering for net proceeds of $9,471,497. In the fourth quarter of the year ended August 31, 2021, the Company received $4,015,043 from the exercise of warrants. We may offer additional securities for sale during our fiscal year 2022 or thereafter in response to market conditions or other circumstances if we believe such a plan of financing is required to advance the Company’s business plans and is in the best interests of our stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern. As of August 31, 2021, the Company had cash and cash equivalents of approximately $10.9m, carries no debt. We believe this is sufficient to enable the Company to fund its operating and R&D expenses and any capital expenditure requirements through one year from the issuance date of the audited consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Impacts of COVID-19 Pandemic</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The emergence of the COVID-19 pandemic in 2020 continues to present uncertainty and unforecastable new risks to the Company and its business plans. As of August 31, 2021, there has been no material impact on the Company’s financial position as a direct result of the pandemic. However, the Company has experienced some supply chain disruptions and shortages in the timely procurement of ingredients and supplies used in both our R&D activities and production. Management views this situation as transitory but cannot predict the length of time it may take for these disruptions to dissipate or if there will be a significant economic effect on the Company’s operations. In the interim, it may cause delays in carrying out our research studies and in our production schedules. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Restrictions on international travel presents a challenge in carrying out normal business activities related to corporate finance efforts and the pursuit of new customers throughout North America who might otherwise access to our licensees’ retail products. As a result, the pandemic has increased the risk of lower revenues and higher losses. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended August 31, 2020, we were in receipt of C$30,732 in COVID relief under the Canada Emergency Wage Subsidy programs for employees which reduced our employment costs in that year. During fiscal 2020 we also received C$40,000 from the Canadian Government sponsored Emergency Business Account loan program. As specified by the terms of this program, we have repaid C$30,000 of the loan in fiscal 2021. The remaining $7,926 (C$10,000) of the loan payable is anticipated to be forgiven as directed under this program in the year ended August 31, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We continue to actively monitor the evolving effects of COVID-19 and may take further actions that alter our operations, including those that may be required by federal, state, provincial, or local authorities, or that we determine are in the best interests of our employees and other third parties with which we do business. We do not know when it will become practical to relax or eliminate some or all these measures entirely. The economic effect of a prolonged pandemic is difficult to predict and could result in material financial impact in the Company’s future reporting periods.</p>
CY2021	lexx	Loss Attributable To Shareholders LossAttributableToShareholders	4200000	USD
CY2020	lexx	Loss Attributable To Shareholders LossAttributableToShareholders	4100000	USD
CY2019	lexx	Loss Attributable To Shareholders LossAttributableToShareholders	4200000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	9471497	USD
CY2021Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4015043	USD
CY2021Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	10900000	USD
CY2021	lexx	Grant Received For Covid Relief GrantReceivedForCovidRelief	30732	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company places its cash with a high credit quality financial institution. As of August 31, 2021, the Company had approximately $10,917,797 on deposit. (August 31, 2020: $1,293,749). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in amounts relievable is $278,107 which represent the value of shares receivable from the sale of assets during the year ended August 31, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the year ended August 31, 2021, one licensee accounted for 72% (2020 – 12%) of revenues.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As at August 31, 2021, we had $Nil (2020 – $143,500) in IP Territory license fees receivable. These receivable amounts are based on contractual terms for payments that are payable within twelve months of signing the definitive agreements or routine IP usage fees. The Company incurred $50,500 in bad debt in fiscal 2021 (2020 – $50,000) primarily due to cancellations of IP license agreements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As at August 31, 2021, the Company had $47,741 (2020 - $87,933) in sales tax receivable. The Company considers its credit risk to be low for such receivables.</p>
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10917797	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1293749	USD
CY2021	us-gaap	Gain Loss On Sale Of Accounts Receivable GainLossOnSaleOfAccountsReceivable	278107	USD
CY2021	lexx	Licensee Accounted Revenues LicenseeAccountedRevenues	0.72	pure
CY2020	lexx	Licensee Accounted Revenues LicenseeAccountedRevenues	0.12	pure
CY2020Q3	lexx	Territory License Fee Receivable TerritoryLicenseFeeReceivable	143500	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50500	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50000	USD
CY2021Q3	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	47741	USD
CY2020Q3	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	87933	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	166043	USD
CY2020Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	483357	USD
CY2021	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	10926	USD
CY2020	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	1928	USD
CY2020	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	160289	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	158773	USD
CY2021	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3. Basis of Consolidation</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries; Lexaria Pharmaceutical Corp., Lexaria Hemp Corp., Lexaria CanPharm ULC, PoViva Corp., and Kelowna Management Services Corp. The Company owns 83.3% of Lexaria Nicotine LLC and the remaining 16.7% is owned by Altria Ventures Inc. (an indirect wholly owned subsidiary of Altria Group, Inc.). All significant intercompany balances and transactions have been eliminated upon consolidation.</p>
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	342401	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	313925	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	29648	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	116871	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	44851	USD
CY2021	lexx	Finished Goods Write Off FinishedGoodsWriteOff	2482	USD
CY2020	lexx	Finished Goods Write Off FinishedGoodsWriteOff	8240	USD
CY2021	lexx	Balance Beginning BalanceBeginning	292000	USD
CY2020	lexx	Balance Beginning BalanceBeginning	265127	USD
CY2021	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	79493	USD
CY2020	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	33645	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6870	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6772	USD
CY2021	lexx	Balance Ending BalanceEnding	364623	USD
CY2020	lexx	Balance Ending BalanceEnding	292000	USD
CY2021Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	649400	USD
CY2021	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	3094	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	278093	USD
CY2021Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	368213	USD
CY2020Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	649400	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	100723	USD
CY2020Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	86920	USD
CY2021	lexx	Stock Issued During Period Shares Stock Warrant Exercised StockIssuedDuringPeriodSharesStockWarrantExercised	610189	shares
CY2021	lexx	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	4015043	USD
CY2021	lexx	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	2102856	shares
CY2021	lexx	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	11039996	USD
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	12178	shares
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	85000	USD
CY2021	lexx	Number Of Shares Issued Under Exercise Of Options And Private Placement And Per Agreements NumberOfSharesIssuedUnderExerciseOfOptionsAndPrivatePlacementAndPerAgreements	2725223	shares
CY2021	lexx	Value Of Shares Issued Under Exercise Of Options And Private Placement And Per Agreements ValueOfSharesIssuedUnderExerciseOfOptionsAndPrivatePlacementAndPerAgreements	15140039	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30030	USD
CY2020	lexx	Stock Issued During Period Shares Private Placement StockIssuedDuringPeriodSharesPrivatePlacement	356332	shares
CY2020	lexx	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	2859916	USD
CY2020	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	11574	shares
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100000	USD
CY2020	lexx	Number Of Shares Issued Under Exercise Of Options And Private Placement And Per Agreements NumberOfSharesIssuedUnderExerciseOfOptionsAndPrivatePlacementAndPerAgreements	375239	shares
CY2020	lexx	Value Of Shares Issued Under Exercise Of Options And Private Placement And Per Agreements ValueOfSharesIssuedUnderExerciseOfOptionsAndPrivatePlacementAndPerAgreements	2989946	USD
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	94177	shares
CY2019Q3	lexx	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	41.50
CY2020	lexx	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	-25000	shares
CY2020	lexx	Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice	45.00
CY2020	lexx	Numbers Of Warrats Issued NumbersOfWarratsIssued	402431	shares
CY2020	lexx	Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice	12.74
CY2020Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	471608	shares
CY2020Q3	lexx	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	16.77
CY2021	lexx	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	-44161	shares
CY2021	lexx	Class Of Warrant Or Right Expirations In Period Weighted Average Exercise Price ClassOfWarrantOrRightExpirationsInPeriodWeightedAverageExercisePrice	67.50
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.36
CY2021	lexx	Numbers Of Warrats Exercised NumbersOfWarratsExercised	-610189	shares
CY2021	lexx	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	6.58
CY2021	lexx	Numbers Of Warrats Issued NumbersOfWarratsIssued	2630017	shares
CY2021	lexx	Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice	6.58
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2447275	shares
CY2021Q3	lexx	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	8.00
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2447275	shares
CY2021	lexx	Weighted Average Remaining Contractual Life WeightedAverageRemainingContractualLife	P3Y11M23D
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The aggregate number of shares issuable under the Equity Incentive Plan is now 510,433 shares, 10% of the Company’s issued share capital at that time.
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	84900	shares
CY2021	lexx	Life Years LifeYears	P5Y
CY2021	lexx	Stock Option Granted StockOptionGranted	87935	shares
CY2021	lexx	Strike Price StrikePrice	9.60
CY2021	lexx	Reissued Stock Price ReissuedStockPrice	7.08
CY2020	lexx	Life Years LifeYears	P5Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	161600	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.66
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	166767	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	149430	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y5M12D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	189003	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.31
CY2020	lexx	Stock Issued During Period Shares Stock Option Exercised StockIssuedDuringPeriodSharesStockOptionExercised	-7333	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.09
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	171604	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.17
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	68713	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y5M8D
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	54723	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	lexx	Usage Fees From Continuing Operations UsageFeesFromContinuingOperations	334974	USD
CY2020	lexx	Usage Fees From Continuing Operations UsageFeesFromContinuingOperations	232909	USD
CY2021	lexx	Loss From Discontinued Operations LossFromDiscontinuedOperations	383179	USD
CY2020	lexx	Loss From Discontinued Operations LossFromDiscontinuedOperations	151634	USD
CY2020Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	58704	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	368213	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	483358	USD
CY2021	lexx	Right Of Use Assets Operating Leases RightOfUseAssetsOperatingLeases	126920	USD
CY2020	lexx	Right Of Use Assets Operating Leases RightOfUseAssetsOperatingLeases	160289	USD
CY2021	lexx	Operating Leases Amortization OperatingLeasesAmortization	-35879	USD
CY2020	lexx	Operating Leases Amortization OperatingLeasesAmortization	-33369	USD
CY2021	lexx	Lease Assets LeaseAssets	91041	USD
CY2020	lexx	Lease Assets LeaseAssets	126920	USD
CY2021	lexx	Operating Lease Liabilities OperatingLeaseLiabilities	125431	USD
CY2020	lexx	Operating Lease Liabilities OperatingLeaseLiabilities	158773	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	43950	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	43764	USD
CY2021	lexx	Operatingleaseinterest Accretion OperatingleaseinterestAccretion	7912	USD
CY2020	lexx	Operatingleaseinterest Accretion OperatingleaseinterestAccretion	10423	USD
CY2021	lexx	Lease Liabilities Operating Lease LeaseLiabilitiesOperatingLease	89393	USD
CY2020	lexx	Lease Liabilities Operating Lease LeaseLiabilitiesOperatingLease	125431	USD
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	91041	USD
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	126920	USD
CY2021	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	43950	USD
CY2020	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	43764	USD
CY2021	lexx	Remaining Lease Term RemainingLeaseTerm	P2Y1M6D
CY2020	lexx	Remaining Lease Term RemainingLeaseTerm	P3Y1M6D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0725	pure
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0725	pure
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	44599	USD
CY2021Q3	lexx	Consulting Consulting	18750	USD
CY2021Q3	lexx	Prepaid Research And Development PrepaidResearchAndDevelopment	0	USD
CY2020Q3	lexx	Prepaid Research And Development PrepaidResearchAndDevelopment	25386	USD
CY2021Q3	lexx	Book Value Of Assets Sold BookValueOfAssetsSold	0	USD
CY2021	lexx	Promissory Note Received On Disposal Of Asset PromissoryNoteReceivedOnDisposalOfAsset	0	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1522704	USD
CY2020	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	5566	USD
CY2020	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-34816	USD
CY2020Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	105250	USD
CY2021Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent	0	USD
CY2020Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent	250	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4169832	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3987018	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-800952	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-856424	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-142895	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	200573	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-56316	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	92083	USD
CY2021	us-gaap	Adjustment For Long Term Intercompany Transactions Tax Expense Benefit AdjustmentForLongTermIntercompanyTransactionsTaxExpenseBenefit	0	USD
CY2020	us-gaap	Adjustment For Long Term Intercompany Transactions Tax Expense Benefit AdjustmentForLongTermIntercompanyTransactionsTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1006256	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	566087	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6093	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2319	USD
CY2021Q3	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	6580183	USD
CY2020Q3	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	5585897	USD
CY2020Q3	lexx	Marketable Securitie MarketableSecuritie	2300	USD
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6594453	USD
CY2020Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5588197	USD
CY2021Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	31621000	USD
CY2021Q3	lexx	Operating Loss Carryforward OperatingLossCarryforward	31183000	USD
CY2021Q3	lexx	Oerating Loss Carry Forward OeratingLossCarryForward	439000	USD
CY2021	lexx	Issuance Of Additional Warrants Shares IssuanceOfAdditionalWarrantsShares	25000	shares
CY2021Q3	lexx	Stock Option Strike Price StockOptionStrikePrice	4.20
CY2021	lexx	Stock Option To Be Issued StockOptionToBeIssued	81800	shares
CY2021	lexx	Consultants Strike Price ConsultantsStrikePrice	6.23

Files In Submission

Name	View Source	Status
0001640334-21-002981-index-headers.html	Edgar Link	pending
0001640334-21-002981-index.html	Edgar Link	pending
0001640334-21-002981.txt	Edgar Link	pending
0001640334-21-002981-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lexx-20210831.xsd	Edgar Link	pending
lexx-20210831_cal.xml	Edgar Link	unprocessable
lexx-20210831_def.xml	Edgar Link	unprocessable
lexx-20210831_lab.xml	Edgar Link	unprocessable
lexx-20210831_pre.xml	Edgar Link	unprocessable
lxrp_10k.htm	Edgar Link	pending
lxrp_10kimg5.jpg	Edgar Link	pending
lxrp_10kimg6.jpg	Edgar Link	pending
lxrp_10k_htm.xml	Edgar Link	completed
lxrp_ex211.htm	Edgar Link	pending
lxrp_ex231.htm	Edgar Link	pending
lxrp_ex231img1.jpg	Edgar Link	pending
lxrp_ex231img2.jpg	Edgar Link	pending
lxrp_ex311.htm	Edgar Link	pending
lxrp_ex312.htm	Edgar Link	pending
lxrp_ex321.htm	Edgar Link	pending
lxrp_ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LEXX
Lexaria Bioscience Corp. Stock $lexx

2021 Form 10-K Financial Statement

#000164033421002981 Filed on November 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LEXX Lexaria Bioscience Corp. Stock $lexx

2021 Form 10-K Financial Statement

#000164033421002981 Filed on November 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LEXX
Lexaria Bioscience Corp. Stock $lexx